In Vivo Screens in Mouse Tumor Models Treated with Pools of Edited CAR-T Cells to Identify the Next Generation of iPSC Derived Immunotherapies for Cancer

Time: 9:00 am
day: Day Two


  • Introduction to Fate’s iPSC Derived Immunotherapy Platform
  • Novel multiplexed approach to generate pools of engineered CAR-T clones with different edits for combinatorial testing in vitro and in vivo
  • Using genomics to screen pools of edited CAR-T in mouse tumor models to identify winning clones with specific edits